Orotic Acid

Orotic Acid

SCHEMBL1461341

C[N+](C)(C)CCO.O=C([O-])c1cc(=O)[nH]c(=O)[nH]1

nearest known ligand 0.46

Full drug profile on Sugi Atlas →

Known targets — ChEMBL curated mechanism

ADORA1ADORA2AADORA2BADORA3GNRHRMPLPDE3APDE3BPDE4APDE4BPDE4CPDE4DPPARASLC5A2

The experimentally established mechanism targets of Orotic Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.46
ALDH1A1 P00352 1/20 0.46
CYP1A2 P05177 1/20 0.45
GPR84 Q9NQS5 5/20 0.40
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
CYP3A4 P08684 1/20 0.35
SLC5A7 Q9GZV3 1/20 0.35
CA1 P00915 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
TSHR P16473 1/20 0.33
HSD17B10 Q99714 1/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
MAPT P10636 2/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Orotic Acid SCHEMBL6754685 0.86 LMNA (0.66) LMNAALDH1A1CYP1A2GPR84MEN1
Orotic Acid SCHEMBL672753 0.85 LMNA (0.57) LMNAALDH1A1CYP1A2GPR84MEN1
Orotic Acid SCHEMBL422601 0.80 LMNA (0.63) LMNAALDH1A1CYP1A2GPR84MEN1
Orotic Acid SCHEMBL9726375 0.80 LMNA (0.63) LMNAALDH1A1CYP1A2GPR84MEN1
Orotic Acid SCHEMBL896843 0.80 LMNA (0.63) LMNAALDH1A1CYP1A2GPR84MEN1
Orotic Acid SCHEMBL23859826 0.80 LMNA (0.63) LMNAALDH1A1CYP1A2GPR84MEN1
Orotic Acid SCHEMBL1854526 0.80 LMNA (0.63) LMNAALDH1A1CYP1A2GPR84MEN1
Orotic Acid SCHEMBL5148012 0.80 LMNA (0.63) LMNAALDH1A1CYP1A2GPR84MEN1
Orotic Acid SCHEMBL20518755 0.80 LMNA (0.63) LMNAALDH1A1CYP1A2GPR84MEN1
Orotic Acid SCHEMBL366202 0.80 LMNA (0.63) LMNAALDH1A1CYP1A2GPR84MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3212191-B1 TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS MEDLAB IP PTY LTD (AU) 2022-10-05 EP claimed
US-11135181-B2 Treatment for depression and depressive disorders MEDLAB IP PTY LTD (AU) 2021-10-05 US claimed
US-20170312232-A1 TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS MEDLAB IP PTY LTD (AU) 2017-11-02 US claimed
EP-3212191-A1 TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS Medlab IP Pty Ltd. (AU) 2017-09-06 EP claimed
WO-2016065419-A1 TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS MEDLAB IP PTY LTD (AU) 2016-05-06 WO claimed
US-20150335688-A1 PROBIOTIC COMBINATIONS AND USES THEREOF MEDLAB IP PTY LTD (AU) 2015-11-26 US claimed
WO-2010005123-A1 COMPOSITION FOR ENHANCING BIOSYNTHESIS OF HYALURONIC ACID OR GLYCOSAMINOGLYCAN COMPRISING OROTIC ACID, A SALT THEREOF, OR A DERIVATIVE THEREOF MAZENCE INC. (KR) 2010-01-14 WO claimed
EP-1537896-B1 Compound mixtures based on sulphur containing amino acids, antioxidants, phospholipids and vitamins for the preparation of a medicament for treating L-diabetes and/or associated diseases. LIEBEL FRANZ-PETER DR (DE) 2008-04-02 EP claimed
US-4061741-A OROTIC ACID OR SALTS FIRMA SERVOMED ARZEI GMBH & CO. PHARMA KG (DT) 1977-12-06 US claimed
EP-3212191-B1 TREATMENT FOR DEPRESSION AND DEPRESSIVE DISORDERS MEDLAB IP PTY LTD (AU) 2022-10-05 EP disclosed
US-11135181-B2 Treatment for depression and depressive disorders MEDLAB IP PTY LTD (AU) 2021-10-05 US disclosed
WO-2020218492-A1 COMPOSITION 興和株式会社 2020-10-29 WO disclosed
WO-2019189714-A1 COMPOSITION 興和株式会社 2019-10-03 WO disclosed
EP-2963023-B1 PROCESS FOR PREPARING 5-AMINO-1, 2, 3-TRIAZOLE OROTATE DERIVATIVES TACTICAL THERAPEUTICS INC (US) 2018-04-18 EP disclosed
CN-101478981-A Pharmaceutical agent for prevention of fatigue and/or recovery from fatigue KOWA CO (JP) 2009-07-08 CN disclosed
WO-2008120070-A2 2(HYDROXYETHYL)TRIMETHYLAMMONIUM THIOCTATE (CHOLINE THIOCTATE) DISPLAYING HEPATOPROTECTIVE, HYPOAMMONIEMIC AND DETOXIC ACTION, A METHOD FOR ITS PRODUCTION AND A PHARMACEUTICAL COMPOSITION BASED THEREON AKTSIONERNE TOVARYSTVO VIDKRYTOGO TYPU «GALYCHFARM» (UA) 2008-10-09 WO disclosed
CN-1935227-A Medicine composition for improving sleep SSP CO LTD (JP) 2007-03-28 CN disclosed
US-20040247686-A1 Pharmaceutical compositions comprising epinastine for the treatment of skin diseases BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-12-09 US disclosed
WO-2004087167-A2 PHARMACEUTICAL COMPOSITIONS COMPRISING EPINASTINE FOR THE TREATMENT OF SKIN DISEASES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2004-10-14 WO disclosed
US-4061741-A OROTIC ACID OR SALTS FIRMA SERVOMED ARZEI GMBH & CO. PHARMA KG (DT) 1977-12-06 US disclosed